RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.59%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$664M
AUM Growth
+$96.5M
Cap. Flow
+$35.6M
Cap. Flow %
5.35%
Top 10 Hldgs %
45.17%
Holding
73
New
23
Increased
14
Reduced
10
Closed
23
Avg Time Held Equity + Options
0.1 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.1 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.1 years

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$37.5M
2
AGN
Allergan plc
AGN
+$36.2M
3
STJ
St Jude Medical
STJ
+$33.9M
4
GILD icon
Gilead Sciences
GILD
+$31.7M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$27.4M

Top Sells

Rank Stock Value
1
ALGN icon
Align Technology
ALGN
+$38.8M
2
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$34.2M
3
CAH icon
Cardinal Health
CAH
+$27.6M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$19.2M
5
CELG
Celgene Corp
CELG
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 80.5%
2 Miscellaneous 17.62%
3 Consumer Staples 1.19%
4 Technology 0.69%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALGN icon
51
Align Technology
ALGN
$10.3B
– –
-1,048,559
Closed -$38.8M –
CAH icon
52
Cardinal Health
CAH
$57.4B
– –
-584,000
Closed -$27.6M –
BGMS icon
53
Bio Green Med Solution Inc
BGMS
$5.92M
– –
-1
Closed -$3.18M –
DVAX icon
54
DELISTED
Dynavax Technologies
DVAX
– –
-5,000
Closed -$55K –
IBB icon
55
iShares Biotechnology ETF
IBB
$10.4B
– –
-4,500
Closed -$261K –
NBIX icon
56
Neurocrine Biosciences
NBIX
$13.8B
– –
-580,500
Closed -$7.77M –
UNH icon
57
UnitedHealth
UNH
$355B
– –
-3,200
Closed -$210K –
WAT icon
58
Waters Corp
WAT
$42.9B
– –
-79,664
Closed -$7.97M –
ZBH icon
59
Zimmer Biomet
ZBH
$17.5B
– –
-183,237
Closed -$13.3M –
MODN icon
60
DELISTED
MODEL N, INC.
MODN
– –
-484,600
Closed -$11.3M –
ABMD
61
DELISTED
Abiomed Inc
ABMD
– –
-326,189
Closed -$7.03M –
CCXI icon
62
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-255,100
Closed -$3.61M –
ALXN
63
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-38,700
Closed -$3.57M –
IPXL
64
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-961,100
Closed -$19.2M –
CPHD
65
DELISTED
Cepheid Inc
CPHD
– –
-318,900
Closed -$11M –
XNPT
66
DELISTED
XENOPORT, INC.
XNPT
– –
-12,500
Closed -$62K –
CYBX
67
DELISTED
CYBERONICS INC
CYBX
– –
-139,100
Closed -$7.23M –
SLXP
68
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-3,300
Closed -$218K –
IDIX
69
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
– –
-30,200
Closed -$109K –
VHS
70
DELISTED
VANGUARD HEALTH SYS INC COM STK (DE)
VHS
– –
-641,955
Closed -$13.3M –
ONXX
71
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
– –
-393,981
Closed -$34.2M –
OREX
72
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-119,044
Closed -$6.96M –
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2013 Portfolio in Review

As of Q3 2013, Redmile Group held 73 positions worth $664M, up 17% from $568M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Redmile Group deployed $35.6M of net new capital in Q3 2013, opening 23 new positions and adding to 14 existing holdings. Its largest new stake was Amgen: 345,700 shares worth $38.7M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Celgene Corp, an estimated $14.3M trimmed.

  • Redmile Group's largest Q3 2013 buy was Amgen: 345,700 shares worth $38.7M.
  • Redmile Group added most to Tenet Healthcare in Q3 2013, an estimated $11.5M increase.
  • Redmile Group's biggest Q3 2013 reduction was Celgene Corp, cutting an estimated $14.3M.
  • Redmile Group fully exited Align Technology in Q3 2013, selling an estimated $38.8M.
  • Redmile Group's ten largest holdings make up 45% of its $664M portfolio in Q3 2013.
  • Redmile Group opened 23 new positions and closed 23 in Q3 2013.
  • Redmile Group's portfolio value rose 17% quarter-over-quarter to $664M.

Based on Redmile Group's 13F filing for Q3 2013, filed 14 Nov 2013.